The Effect of Antipsychotics and Their Combinations with Other Psychotropic Drugs on Electrocardiogram Intervals Other Than QTc among Jordanian Adult Outpatients
by
,
Nailya Bulatova
1,*,
Noor Altaher
1,
Radwan BaniMustafa
2,
Akram Al-Saleh
2,
Haya Yasin
1,
Mohammed Zawiah
1,
Hala Khalefah
1,
Mokhtar Ghilan
2,
Ala’a Al-Lahham
2,
Mohummad Hudaib
2,
Batoul AlKhawaldeh
1 and
Mahmoud Nasr
2 1
Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, The University of Jordan, Amman 11942, Jordan
2
Department of Internal Medicine, School of Medicine, The University of Jordan, Amman 11942, Jordan
*
Author to whom correspondence should be addressed.
Biomedicines 2023, 11(1), 13; https://doi.org/10.3390/biomedicines11010013
Submission received: 19 November 2022
/
Revised: 15 December 2022
/
Accepted: 19 December 2022
/
Published: 22 December 2022
(This article belongs to the Special Issue Antipsychotics: 70 Years)
Abstract
:The ECG changes produced by antipsychotics and other psychotropic medications are studied mostly regarding QTc interval prolongation. This study aimed to investigate ECG changes beyond long QTc interval produced by psychotropic medications. A cross-sectional study was conducted to assess the effect of these agents on RR, PR, TpTe intervals and TpTe/QT ratio among Jordanian outpatients. The RR interval was significantly shorter among patients on TCAs versus those not receiving TCAs and among patients on polytherapy versus those on monotherapy (p < 0.05 for both comparisons), when adjusted for age, gender, BMI, caffeine intake, smoking, presence of diabetes mellitus, cardiovascular disease and medications known to produce heart rate changes. Positive correlations were found between the PR interval and age in patients treated with SGAs, SSRIs, citalopram, polytherapy and in the total sample (p < 0.01 for all). Inverse correlations were found between the RR interval and the number of psychotropic medications among patients treated with SSRIs and in the whole study sample (p < 0.01 for both). In conclusion, various ECG changes beyond QTc interval prolongation are observed in patients on antipsychotics and other psychotropic medications, in those on polytherapy. It is recommended to obtain an ECG before starting patients on psychotropic drugs known to produce electrocardiographic changes and their combinations.
1. Introduction
Patients with mental disorders who receive antipsychotics and other psychotropic medications have higher mortality compared to the general population [1]. Sudden cardiac death (SCD) accounted for 15–40% of sudden unexpected deaths in schizophrenia while around 10% of SCD may be due to arrhythmias from cardiac electric defects that can be detected by electrocardiogram (ECG) [2]. Several antipsychotics have been shown to produce ECG changes and the most investigated is prolongation of QTc interval [3,4], which is known to predict a polymorphic ventricular tachyarrhythmia, torsade de points (TdP) that, in turn, may result in sudden cardiac death (SCD) [5].
The ECG changes other than long QTc interval (LQTc) produced by antipsychotics and other psychotropic agents, are much less studied. They include changes in duration of QRS interval (which reflects the depolarization of the ventricles) [6] and PR interval (the period between the onset of atrial depolarization and the onset of ventricular depolarization) [7], heart rate [8,9] which is inversely associated with the RR interval, morphological changes of P and T waves [2,10], axis deviation, pathological Q wave [2,11] and ST-segment abnormality [2]. Among patients with schizophrenia who were switched from olanzapine to risperidone, a significant decrease in PR interval, but no change in RR interval were observed [7]. In another study, schizophrenia patients developed a decrease in low to high frequency power, an index of heart rate variability, after six weeks of risperidone treatment [8]. A comparison of P-wave duration and P-wave dispersion (measures of proneness to atrial fibrillation) between schizophrenia patients and healthy volunteers after parenteral zisperidone administration showed that the initial P-wave dispersion was significantly longer in patients than in healthy controls [9]. In 37 patients switched to sertindole, prominent T-wave morphology changes occurred, sometimes without concomitant prolongation of the QTcF interval [10]. Among 4486 Danish schizophrenia patients, ECG characteristics were investigated in association with psychotropic drugs, where patients with schizophrenia demonstrated higher median heart rate and pathological Q waves than controls. Among patients with schizophrenia only, redeemed prescriptions of antipsychotics (most notably, clozapine and with the exception of aripiprazole), antipsychotic polypharmacy and benzodiazepines were associated with abnormal ECGs. On the other hand, redeemed prescriptions of antidepressants, with the exception of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and lithium, were not associated with differential risk of abnormal ECGs [11]. In the chart audit of 169 patients with schizophrenia and schizoaffective disorder in a long-stay inpatient unit, more than half (52.1%) had at least one ECG abnormality other than long QTc interval, and one-fifth (20.7%) had two or more ECG abnormalities [2].
TpTe interval and TpTe/QT ratio are being used increasingly in the assessment of arrhythmogenicity. TpTe is the time interval measured from the peak of the T wave to the end of the T wave, which coincides with the repolarization time of epicardium cells until the completion of myocardial M cell repolarization. Prolonged TpTe interval is associated with increased transmual dispersion of repolarization (TDR), which, in turn, is associated with the occurrence of ventricular tachycardia (VT) [12]. We found two studies that investigated the effect of antipsychotics on the TpTe interval and TpTe/QT ratio. In children with attention deficit disorder, the TpTe and TpTe/QT ratio were significantly higher in the risperidone group compared to that of the untreated group [13]. In a randomized double-blind study in schizophrenia patients, treatment with sertindole was associated with an increase in TpTe, along with other ECG changes, while quetiapine caused no increase in TpTe compared to baseline. Although quetiapine (400–600 mg) did not show worsening of repolarization measures, some individual patients did experience significant worsening of repolarization [14]. Studies related to TpTe interval and TpTe ratio changes produced by antidepressants are confined to one study of amitriptyline poisoning in pigs, which found no changes in these parameters [15].
A very few studies investigated the effect of antipsychotics’ combinations on the ECG, most commonly on the QTc interval [1,16,17], including a recent publication by our group [18]. A recent study reported ECG abnormalities in relation to psychotropic polypharmacy in schizophrenia and schizoaffective disorders [2].
In order to address the knowledge gap in this area, this study aimed to investigate ECG changes other than LQTc (duration of RR, PR and TpTe intervals and TpTe/QT ratio) in Jordanian patients treated with antipsychotics and their combinations.
2. Materials and Methods
This is a part of the cross-sectional study that investigated the prevalence of LQTc among Jordanian patients treated with psychotropic drugs. The study was conducted in the outpatient psychiatric clinics at Jordan University Hospital (JUH) from March 2018 till March 2019. The study received ethical approval from the Institutional Review Board (IRB) of the JUH. The part of the study that reported QTc interval changes was recently published and contains further methodology details [18]. A surface ECG was recorded in a supine position after a 5-min rest using a 12-lead Mortara ELI 230 portable ECG recorder (25 mm/s paper speed, 10 mm/mV amplitude). The ECG records were analyzed by a fellow in cardiology who was blind to the patients’ condition, study hypothesis, and treatment status and was not involved in the patients’ care.
ECG parameters measured:
- RR interval
- PR interval
- TpTe interval [the interval between the peak and the end of the T wave (Tpeak to Tend)] [19]
- TpTe interval divided by QT interval
- Morphological changes of T wave
- Fragmented QRS
All measurements were conducted in the standard lead II.
All statistical analyses were performed using SPSS version 22 (IBM Corp.; Armonk, NY, USA). The Kolmogorov-Smirnov and Shapiro-Wilk tests were conducted for the normality of data distribution. Frequencies and mean values with standard deviations (SD) were calculated. For the comparison of continuous variables between two treatment groups, Quade’s test (a non-parametric ANCOVA) was performed with the following confounding factors: age, gender, BMI, smoking, caffeine intake, presence of diabetes mellitus, cardiovascular disease and medications known to produce either bradycardia (beta-blockers or calcium channel blockers) or tachycardia (beta2-adrenergic agonists or thyroid hormones). To assess the differences in continuous variables between multiple groups for non-normally distributed data, the Kruskal-Wallis test was conducted and followed by the Mann-Whitney U test. Pearson correlation was conducted to assess relationship of different ECG parameters with age and the number of psychotropic medications.
p-values < 0.05 were considered statistically significant.
3. Results
3.1. Patient Demographic and Clinical Data
Three hundred and seven patients were included in the study; the mean age was 36.3 ± 13.5 years; 140 (45.6%) patients were males and 167 (54.4%) were females (Table 1). The mean BMI was 26.7 ± 5.1; 36.8% of patients were smokers and 75.9% admitted caffeine intake.
Anxiety disorder was the most common psychiatric condition among study participants (41.4%), followed by major depressive disorder (28.7%), bipolar disorder (17.3%) and schizophrenia (4.9%). The most common nonpsychiatric conditions were hypertension (8.4%) and diabetes mellitus (5.6%). Medications known to produce tachycardia (beta2 adrenergic agonists and thyroid hormones) were prescribed to 7 (2.3%) patients, and 12 (3.9%) patients were on medications known to produce bradycardia (beta-blockers and calcium channel blockers).
3.2. Description of Psychotropic Medications
The most commonly prescribed psychotropic medications were selective serotonin reuptake inhibitors (SSRIs) (73.4%) and second-generation antipsychotics (SGAs) (51.5%), followed by mood stabilizers (22.4%), tricyclic antidepressants (TCAs) (11.4%), and first-generation antipsychotics (FGAs) (9.8%) (Figure 1).
As for individual psychotropic drugs, the most commonly prescribed among SSRIs were citalopram and fluoxetine (52.2% and 28.2%, respectively), among TCAs were melitracen and amitriptyline (51.4% and 37.1%, respectively) among FGAs was flupentixol (78.8%), among SGAs were quetiapine and olanzapine (46.2% and 27.9%, respectively), among mood stabilizers were valproate and lamotrigine (39.1% and 30.4%, respectively) and among benzodiazepines was bromazepam (70.8%) (Table 2).
More than half of patients (n = 184; 59.9%) received combined psychotropic therapy. The mean number of psychotropic medications was 1.81 ± 0.81, ranging between 1 and 5. A large proportion of patients received two (n = 128; 41.7%) and 48 patients (15.6%) received three psychotropic medications (Figure 2).
Among psychotropic drug combinations, the most frequent was SSRIs with SGAs (32.9%), followed by SGAs with mood stabilizers (14.3%) and SSRIs with mood stabilizers (9.8%). A triple combination of SSRIs, SGAs and mood stabilizers occurred in 6.8% of cases (Figure 3).
3.3. ECG Changes Caused by Psychotropic Drugs
The RR interval was significantly shorter among patients on TCAs versus those not receiving TCAs and among patients on polytherapy versus those on monotherapy (p < 0.05 for both comparisons) after adjusting for confounding factors such as age, gender, BMI, smoking, caffeine intake, presence of diabetes mellitus, cardiovascular disease and medications known to produce heart rate changes (Table 3).
The Kruskal-Wallis Test was conducted to examine the effect of the most common psychotropic combination, SSRIs and SGAs, in comparison to either SSRIs or SGAs or none of these medications on RR, PR, TpTe and TpTe/QT intervals (Table 4). The test provided evidence of a difference (p < 0.05) between the mean ranks of RR interval of at least one pair of groups. Pairwise Mann-Whitney U tests were carried out for the four pairs of groups for RR interval. There was strong evidence (p < 0.01, adjusted for the number of pairs being tested) of a shorter RR interval among patients who received SGAs compared to those who received SSRIs. The median RR interval for patients treated with SGAs was 750 ms compared to 800 ms for those on SSRIs. There was no evidence of a difference between the other pairs. We did not find difference in PR, TpTe and TpTe/QT intervals between the SSRI + SGA combination and either SSRIs or SGAs or none of these medications.
Table 5 presents correlations of RR, PR, TpTe intervals and TpTe/QT with patient age, BMI and number of psychotropic drugs. No correlations were found in the quetiapine and mood stabilizers groups. Positive correlations were found between the PR interval and age in patients treated with SGAs (r = 0.282; p = 0.001), SSRIs (r = 0.247; p = 0.001), citalopram (r = 0.330; p = 0.001), polytherapy (r = 0.236; p = 0.002) and in the total sample (r = 0.252; p = 0.001). Inverse correlations were found between the RR interval and the number of psychotropic medications among patients treated with SSRIs (r = −0.178; p = 0.007) and in the whole study sample (r = −0.174; p = 0.002). None of the ECG parameters correlated with BMI.
We found that one patient (0.3%) had premature ventricular contractions (PVCs) and another one (0.3%) had biphasic T wave. The patient with PVC was a 55-year-old female, overweight (BMI 28.9), smoker, daily caffeine intake 3 cups of coffee, no comorbidities, main psychiatric diagnosis bipolar disorder, on quetiapine (400 mg BID) and lamotrigine (25 mg BID), with a heart rate of 106 BPM. The patient with biphasic T wave was a 38-year-old male, smoker, daily caffeine intake 8 cups of coffee, type 2 DM, main psychiatric diagnosis bipolar disorder, on fluoxetine (20 mg TID), haloperidol (5 mg BID), olanzapine (10 mg QD), alprazolam (0.5 mg BID) and procyclidine (5 mg BID); his heart rate was 99 BPM. No QTc prolongation was determined in both cases.
4. Discussion
In this cross-sectional study, we investigated the effect of antipsychotics and other psychotropic drugs on the ECG parameters other than QTc interval in Jordanian outpatients with mental illness, with special emphasis on polypharmacy. Polypharmacy relates to the use of more than one medication, typically with a complex medication dosing schedule. However, there is no adequate evidence to support the safety and efficacy of such treatment regimens [1].
It is well known that high resting heart rate is independently associated with increased risk of cardiovascular mortality [20,21]. FGAs, SGAs and TCAs have been previously associated with a shorter RR interval [22,23,24] due to the presence of α2 adrenoceptor- and muscarinic blocking effect [1]. In our study, the RR interval was significantly shorter among patients on TCAs versus those not receiving TCAs. Such effects were previously reported by van Zyl et al. [25]. As expected, patients receiving polytherapy had significantly shorter RR intervals compared to those on monotherapy, as many of the medications prescribed from the antipsychotic and antidepressant classes have antimuscarinic effects.
Prolongation of the TpTe interval [the interval between the peak and the end of the T wave (Tpeak to Tend)], a measure of cardiac transmural dispersion of repolarization, is associated with higher risk of SCD via increased susceptibility to early and late afterdepolarizations [19]. In a cross-sectional study that involved psychiatric inpatients, clozapine increased TpTe [26], and in a randomized double-blind study in schizophrenia patients, sertindole increased TpTe, while quetiapine caused no increase in TpTe [14]. However, the authors of the latter study noted that, although quetiapine did not show worsening of repolarization measures, some individual patients did experience significant worsening of repolarization [14]. We failed to confirm the above data on the effect of quetiapine on TpTe and TpTe/QT ratio.
Positive correlations were found between the PR interval and age consistently in patients treated with SGAs, SSRIs, citalopram, polytherapy and in the total sample (p < 0.01 for all). Such correlations are reported for the first time among patients treated by psychotropic agents. Inverse correlations were found between the RR interval and the number of psychotropic medications among patients treated with SSRIs and in the whole study sample (p < 0.01 for both), in support of the above data comparing patient on monotherapy vs. those on polytherapy. In contrast, the use of multiple antipsychotics, with or without other psychotropic drugs, was not significantly associated with the presence or number of ECG abnormalities in patients with schizophrenia and schizoaffective disorder in a long-stay inpatient unit [2].
We report one case of PVC and another one of biphasic T wave, both patients treated with antipsychotics (quetiapine and a combination of haloperidol and olanzapine, respectively). The resting heart rate was elevated in both patients, and this is known to be associated with SCD risk. Our findings are consistent with those of a recent study among patients with schizophrenia, where redeemed prescriptions of antipsychotics and antipsychotic polypharmacy were associated with abnormal ECGs [11]. However, the recent observational studies found no significant difference in mortality between patients on antipsychotic polypharmacy vs. those on monotherapy [1].
Study limitations include its cross-sectional observational nature, which does not allow to the drawing of the causation of ECG abnormalities (e.g., mental disease vs. psychotropic medications). We did not consider medication adherence, duration of mental disease or pharmacological treatment. Future large prospective studies are recommended that will address all the above issues, as well as the relation of ECG changes to SCD in patients on antipsychotics and other psychotropic medications.
5. Conclusions
Various ECG changes beyond QTc interval prolongation are observed in patients on antipsychotics and other psychotropic medications, and in those on polytherapy. It is recommended to obtain an ECG before starting patients on psychotropic drugs known to produce electrocardiographic changes and their combinations.
Author Contributions
Conceptualization, N.B. and A.A.-S.; data curation, N.A.; formal analysis, N.B. and H.K.; funding acquisition, N.B.; investigation, N.A., H.Y., M.Z., H.K., M.G., A.A.-L., M.H., B.A. and M.N.; methodology, N.B., N.A. and R.B.; project administration, H.Y., M.Z. and H.K.; resources, N.B. and N.A.; software, N.B.; supervision, N.B. and N.A.; validation, N.A., H.Y. and M.Z.; visualization, N.B.; writing—original draft, N.B., A.A.-S. and H.K.; writing—review & editing, N.B., N.A., R.B., A.A.-S., H.Y., M.Z., H.K., M.G., A.A.-L., M.H., B.A. and M.N. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by the Deanship of Scientific Research, The University of Jordan, grant number 2017-2016/89, date: 14 March 2017.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of The Jordan University Hospital (protocol code 2017/77, date: 11 April 2017).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
Data presented in this study are available at the corresponding author on reasonable request.
Acknowledgments
The authors thank the nursing staff of the psychiatry clinic at the Jordan University Hospital and all patients involved in the study. We are also grateful to Ahmad Hajjar and Amjad AlZeer for their assistance in data collection and ECG recording.
Conflicts of Interest
The authors declare no conflict of interest. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
References
- Edinoff, A.N.; Ellis, E.D.; Nussdorf, L.M.; Hill, T.W.; Cornett, E.M.; Kaye, A.M.; Kaye, A.D. Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review. Neurol. Int. 2022, 14, 294–309. [Google Scholar] [CrossRef] [PubMed]
- Tirupati, S.; Gulati, S. Electrocardiographic abnormalities and psychotropic polypharmacy in schizophrenia and schizoaffective disorders. Australas Psychiatry 2022, 30, 243–246. [Google Scholar] [CrossRef] [PubMed]
- Fabbri, C.; Boriani, G.; Diemberger, I.; Filippi, M.G.; Ravegnini, G.; Hrelia, P.; Minarini, A.; Albani, D.; Forloni, G.; Angelini, S.; et al. Electrocardiogram Alterations Associated with Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. Basic Clin. Pharmacol. Toxicol. 2017, 120, 482–490. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Corponi, F.; Fabbri, C.; Boriani, G.; Diemberger, I.; Albani, D.; Forloni, G.; Serretti, A. Corrected QT Interval Prolongation in Psychopharmacological Treatment and its Modulation by Genetic Variation. Neuropsychobiology 2019, 77, 67–72. [Google Scholar] [CrossRef]
- Darpö, B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur. Heart J. 2001, 3, K70–K80. [Google Scholar] [CrossRef] [Green Version]
- Madias, J.E. Drug-induced QRS morphology and duration changes. Cardiol. J. 2008, 15, 505–509. [Google Scholar]
- Suzuki, Y.; Sugai, T.; Ono, S.; Sawamura, K.; Fukui, N.; Watanabe, J.; Tsuneyama, N.; Saito, M.; Someya, T. Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia. Psychiatry Clin Neurosci 2014, 68, 353–356. [Google Scholar] [CrossRef] [Green Version]
- Chang, J.S.; Yoo, C.S.; Yi, S.H.; Hong, K.H.; Lee, Y.S.; Oh, H.S.; Jung, D.C.; Kim, Y.S.; Ahn, Y.M. Changes in heart rate dynamics of patients with schizophrenia treated with risperidone. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34, 924–929. [Google Scholar] [CrossRef]
- Emul, M.; Dalkiran, M.; Coskun, O.; Yavuz, R.; Tosun, M.; Duran, A.; Ugur, M.; Keles, I. P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration. Pharmacol. Res. 2009, 60, 369–372. [Google Scholar] [CrossRef]
- Nielsen, J.; Graff, C.; Hardahl, T.; Andersen, M.P.; Kristoffersen, J.; Struijk, J.J.; Toft, E.; Meyer, J.M. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur. Neuropsychopharmacol. 2009, 19, 702–707. [Google Scholar] [CrossRef]
- Polcwiartek, C.; Kragholm, K.; Hansen, S.M.; Atwater, B.D.; Friedman, D.J.; Barcella, C.A.; Graff, C.; Nielsen, J.B.; Pietersen, A.; Nielsen, J.; et al. Electrocardiogram Characteristics and Their Association with Psychotropic Drugs Among Patients with Schizophrenia. Schizophr. Bull. 2020, 46, 354–362. [Google Scholar] [CrossRef] [PubMed]
- Nugraheni, A.P.; Arso, I.A.; Maharani, E. Association of Tp-Te/QT Ratio with Ventricular Tachycardia in Patients with Idiopathic Outflow Tract Ventricular Premature Contraction. Cardiol. Res. 2018, 9, 215–223. [Google Scholar] [CrossRef] [Green Version]
- Karpuz, D.; Hallioglu, O.; Toros, F.; Tasdelen, B. The effect of metilpheniydate, risperidone and combination therapy on ECG in children with attention-deficit hyperactivity disorder. J. Electrocardiol. 2017, 50, 410–415. [Google Scholar] [CrossRef]
- Nielsen, J.; Matz, J.; Mittoux, A.; Polcwiartek, C.; Struijk, J.J.; Toft, E.; Kanters, J.K.; Graff, C. Cardiac effects of sertindole and quetiapine: Analysis of ECGs from a randomized double-blind study in patients with schizophrenia. Eur. Neuropsychopharmacol. 2015, 25, 303–311. [Google Scholar] [CrossRef]
- Jansen, T.; Hoegberg, L.C.G.; Eriksen, T.; Haarmark, C.; Dalhoff, K.; Belhage, B. Advanced Electrocardiogram Analysis in the Amitriptyline-poisoned Pig Treated with Activated Charcoal Haemoperfusion. Basic. Clin. Pharmacol. Toxicol. 2018, 122, 442–447. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nosè, M.; Bighelli, I.; Castellazzi, M.; Martinotti, G.; Carrà, G.; Lucii, C.; Ostuzzi, G.; Sozzi, F.; Barbui, C.; Star Network Group. Prevalence and correlates of QTc prolongation in Italian psychiatric care: Cross-sectional multicentre study. Epidemiol. Psychiatr. Sci. 2016, 25, 532–540. [Google Scholar] [CrossRef] [PubMed]
- Takeuchi, H.; Suzuki, T.; Remington, G.; Uchida, H. Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. Can. J. Psychiatry 2015, 60, 215–222. [Google Scholar] [CrossRef] [Green Version]
- Bulatova, N.R.; Altaher, N.; Banimustafa, R.; Al-Saleh, A.; Yasin, H.; Zawiah, M.; Khalefah, H.M.; Younes, S.; Al-Lahham, A.J.; Hudaib, M.I.; et al. The Effect of Psychotropic Medications and Their Combinations on the QTc Interval Among Jordanian Outpatients: A Cross-Sectional Study. Alapha Psychiatry 2021, 22, 177–184. [Google Scholar] [CrossRef]
- Panikkath, R.; Reinier, K.; Uy-Evanado, A.; Teodorescu, C.; Hattenhauer, J.; Mariani, R.; Gunson, K.; Jui, J.; Chugh, S.S. Prolonged Tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death. Circ. Arrhythm. Electrophysiol. 2011, 4, 441–447. [Google Scholar] [CrossRef] [Green Version]
- Fox, K.M.; Ferrari, R. Heart rate: A forgotten link in coronary artery disease? Nat. Rev. Cardiol. 2011, 8, 369–379. [Google Scholar] [CrossRef]
- Hottigoudar, R.U.; Gopinathannair, R. ‘Inappropriate’ sinus tachycardia: Does the 100 beats per min cut-off matter? Future Cardiol. 2013, 9, 273–288. [Google Scholar] [CrossRef] [PubMed]
- Gopal, S.; Hough, D.; Karcher, K.; Nuamah, I.; Palumbo, J.; Berlin, J.A.; Baseman, A.; Xu, Y.; Kent, J. Risk of cardiovascular morbidity with risperidone or paliperidone treatment: Analysis of 64 randomized, double-blind trials. J. Clin. Psychopharmacol. 2013, 33, 157–161. [Google Scholar] [CrossRef] [PubMed]
- Hasnain, M.; Vieweg, W.V.; Howland, R.H.; Kogut, C.; Breden Crouse, E.L.; Koneru, J.N.; Hancox, J.C.; Digby, G.C.; Baranchuk, A.; Deshmukh, A.; et al. Quetiapine and the need for a thorough QT/QTc study. J. Clin. Psychopharmacol. 2014, 34, 3–6. [Google Scholar] [CrossRef] [PubMed]
- Schneider, C.; Corrigall, R.; Hayes, D.; Kyriakopoulos, M.; Frangou, S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur. Psychiatry 2014, 29, 1–10. [Google Scholar] [CrossRef] [PubMed]
- van Zyl, L.T.; Hasegawa, T.; Nagata, K. Effects of antidepressant treatment on heart rate variability in major depression: A quantitative review. Biopsychosoc. Med. 2008, 2, 12. [Google Scholar] [CrossRef] [Green Version]
- Acciavatti, T.; Martinotti, G.; Corbo, M.; Cinosi, E.; Lupi, M.; Ricci, F.; Di Scala, R.; D’Ugo, E.; De Francesco, V.; De Caterina, R.; et al. Psychotropic drugs and ventricular repolarisation: The effects on QT interval, T-peak to T-end interval and QT dispersion. J. Psychopharmacol. 2017, 31, 453–460. [Google Scholar] [CrossRef]
Figure 1.
Frequency of psychotropic medications classes (n = 307).
Figure 2.
Number of psychotropic medications prescribed.
Figure 3.
Frequencies of psychotropic classes combinations (n = 307).
Table 1.
General Characteristics of the Study Participants (n = 307).
| Patient Characteristic | |
|---|---|
| Gender, n (%) | |
| Male | 141 (45.9) |
| Female | 166 (54.1) |
| Age, Mean (SD) (range) | 36.26 (13.48) (18–81) |
| BMI, Mean (SD) (range) | 26.66 (5.07) (16.40–47.94) |
| Smoker, a n (%) | 113 (36.8) |
| Alcohol, a n (%) | 10 (3.3) |
| Caffeine, a n (%) | 233 (75.9) |
| Physical activity, a n (%) | 61 (19.9) |
| Psychiatric conditions, n (%) | |
| Anxiety disorders | 127 (41.4) |
| Major depressive disorder | 88 (28.7) |
| Bipolar disorder | 53 (17.3) |
| Schizophrenia | 15 (4.9) |
| Others | 24 (7.8) |
| Non-psychiatric conditions, n (%) | |
| Cardiovascular disease b | 34 (5.9) |
| Hypertension | 26 (8.4) |
| Diabetes mellitus | 17 (5.6) |
| Hypothyroidism | 5 (1.6) |
| Epilepsy | 5 (1.6) |
| Asthma | 4 (1.3) |
| Others | 24 (7.8) |
a Most days of the week of any amount; b including hypertension.
Table 2.
Frequency of individual psychotropic medications.
| Name of Class and Medication | Frequency | % |
|---|---|---|
| SSRIs | 226 | 100 |
| Citalopram | 118 | 52.2 |
| Fluoxetine | 65 | 28.2 |
| Fluvoxamine | 19 | 8.4 |
| Escitalopram | 17 | 7.5 |
| Sertraline | 4 | 1.8 |
| Paroxetine | 3 | 1.3 |
| SNRIs | 3 | 100 |
| Venlafaxine | 2 | 66.7 |
| Duloxetine | 1 | 33.3 |
| TCAs | 35 | 100 |
| Melitracen | 18 | 51.4 |
| Amitriptyline | 13 | 37.1 |
| Clomipramine | 4 | 11.4 |
| Other antidepressants | ||
| Mirtazapine | 8 | 100 |
| FGAs | 33 | 100 |
| Flupentixol | 26 | 78.8 |
| Haloperidol | 3 | 9.1 |
| Sulpiride | 1 | 3.0 |
| Zuclopentixol | 3 | 9.1 |
| SGAs | 158 | 100 |
| Quetiapine | 73 | 46.2 |
| Olanzapine | 44 | 27.9 |
| Risperidone | 29 | 18.4 |
| Amisulpiride | 7 | 4.4 |
| Aripiprazole | 2 | 1.3 |
| Clozapine | 2 | 1.3 |
| Ziprasidone | 1 | 0.6 |
| Mood stabilizers | 69 | 100 |
| Valproate | 27 | 39.1 |
| Lamotrigine | 21 | 30.4 |
| Lithium | 13 | 18.8 |
| Carbamazepine | 8 | 11.6 |
| Benzodiazepines | 24 | 100 |
| Bromazepam | 17 | 70.8 |
| Alprazolam | 5 | 20.8 |
| Clonazepam | 2 | 8.3 |
FGAs: first generation antipsychotics, TCAs: tricyclic antidepressants; SGAs: second generation antipsychotics, SNRIs: serotonin and norepinephrine reuptake inhibitors; SSRIs: selective serotonin reuptake inhibitors.
Table 3.
Effect of the most commonly prescribed psychotropic therapies on RR, PR TpTe intervals and TpTe/QT.
Table 3.
Effect of the most commonly prescribed psychotropic therapies on RR, PR TpTe intervals and TpTe/QT.
| Therapy | QT # (ms) (Uncorrected) | RR (ms) | PR (ms) | TpTe (ms) | TpTe/QT |
|---|---|---|---|---|---|
| FGAs | |||||
| Yes (n = 33) | 366 ± 23 | 762 ± 142 | 152 ± 20 | 76 ± 16 | 0.21 ± 0.04 |
| No (n = 274) | 371 ± 28 | 806 ± 132 | 148 ± 19 | 84 ± 93 | 0.22 ± 0.23 |
| F | 2.97 | 2.72 | 0.30 | 0.01 | |
| p-value | 0.086 | 0.100 | 0.58 | 0.94 | |
| SGAs | |||||
| Yes (n = 159) | 369 ± 27 | 783 ± 129 | 146 ± 18 | 84 ± 96 | 0.24 ± 0.24 |
| No (n = 148) | 373 ± 28 | 821 ± 1362.66 | 150 ± 193.19 | 81 ± 790.01 | 0.22 ± 0.19 |
| F | 0.10 | 0.08 | 1.00 | 0.6 | |
| p-value | |||||
| Quetiapine | |||||
| Yes (n = 73) | 368 ± 26 | 780 ± 125 | 148 ± 17 | 97 ± 14 | 0.26 ± 0.35 |
| No (n = 234) | 371 ± 28 | 808 ± 136 | 148 ± 19 | 78 ± 64 | 0.21 ± 0.16 |
| F | 0.83 | 0.02 | 0.41 | 0.37 | |
| p-value | 0.36 | 0.92 | 0.52 | 0.54 | |
| SSRIs | |||||
| Yes (n = 226) | 375 ± 27 | 814 ± 134 | 148 ± 18 | 86 ± 10 | 0.23 ± 0.25 |
| No (n = 81) | 359 ± 26 | 767 ± 127 | 148 ± 21 | 72 ± 18 | 0.20 ± 0.05 |
| F | 3.73 | 0.01 | 0.07 | 0.62 | |
| p-value | 0.06 | 0.94 | 0.80 | 0.43 | |
| Citalopram | |||||
| Yes (n = 118) | 376 ± 29 | 814 ± 137 | 150 ± 18 | 75 ± 19 | 0.20 ± 0.05 |
| No (n = 189) | 367 ± 26 | 794 ± 132 | 147 ± 19 | 87 ± 12 | 24 ± 0.27 |
| F | 0.32 | 1.07 | 0.19 | 0.01 | |
| p-value | 0.58 | 0.30 | 0.66 | 0.91 | |
| TCAs | |||||
| Yes (n = 35) | 369 ± 21 | 759 ± 109 | 152 ± 13 | 74 ± 13 | 0.20 ± 0.05 |
| No (n = 271) | 371 ± 28 | 808 ± 136 | 148 ± 19 | 84 ± 93 | 0.23 ± 0.23 |
| F | 5.93 | 1.81 | 0.08 | 0.01 | |
| p-value | 0.02 | 0.18 | 0.77 | 0.96 | |
| Mood stabilizers | |||||
| Yes (n = 69) | 363 ± 27 | 784 ± 132 | 149 ± 21 | 73 ± 16 | 0.20 ± 0.04 |
| No (n= 238) | 373 ± 27 | 807 ± 134 | 148 ± 18 | 86 ± 100 | 0.23 ± 0.25 |
| F | 0.89 | 0.01 | 0.38 | 0.01 | |
| p-value | 0.35 | 0.96 | 0.54 | 0.95 | |
| Polytherapy | |||||
| Yes (n = 184) | 369 ± 27 | 782 ± 127 | 148 ± 20 | 81 ± 87 | 0.23 ± 0.22 |
| No (n = 123) | 372 ± 28 | 830 ± 1397.61 | 148 ± 19 | 83 ± 89 | 0.22 ± 0.21 |
| F | 0.01 | 0.02 | 0.18 | 0.01 | |
| p-value | 0.88 | 0.68 | 0.96 |
Significant differences are shown in bold fonts; values in bold indicate significant differences in Quade’s test, with adjusting for: age, gender, BMI, smoking, caffeine intake, presence of diabetes mellitus, cardiovascular disease and presence of medications known to produce either bradycardia (beta-blockers or calcium channel blockers) or tachycardia (beta2-adrenergic agonists or thyroid hormones); # comparisons for QT interval were not conducted as it was used for TpTe/QT calculation only. FGAs: first generation antipsychotics, TCAs: tricyclic antidepressants; SGAs: second generation antipsychotics, SSRIs: selective serotonin reuptake inhibitors.
Table 4.
The effect of SGA and SSRI combination on RR, PR, TpTe intervals and TpTe/QT.
| Interval | Type of Therapy | n | Mean Rank | X2 |
|---|---|---|---|---|
| RR | None | 23 | 148 | 5.79 |
| SSRI | 125 | 170 | ||
| SGA | 58 | 124 | ||
| SSRI + SGA | 101 | 153 | ||
| PR | None | 23 | 177 | 4.87 |
| SSRI | 125 | 163 | ||
| SGA | 58 | 138 | ||
| SSRI + SGA | 101 | 147 | ||
| TpTe | None | 23 | 146 | 4.47 |
| SSRI | 123 | 153 | ||
| SGA | 55 | 144 | ||
| SSRI + SGA | 100 | 153 | ||
| TpTe/QT | None | 23 | 165 | |
| SSRI | 123 | 148 | ||
| SGA | 55 | 158 | 1.57 | |
| SSRI + SGA | 100 | 148 |
By Kruskal-Wallis test.
Table 5.
Correlations of RR, PR TpTe intervals and TpTe/QT with age, BMI and number of psychotropic drugs in the total sample and in patients prescribed the most common psychotropic medications.
Table 5.
Correlations of RR, PR TpTe intervals and TpTe/QT with age, BMI and number of psychotropic drugs in the total sample and in patients prescribed the most common psychotropic medications.
| RR (ms) | PR (ms) | TpTe (ms) | TpTe/QT | ||
|---|---|---|---|---|---|
| SGAs (n = 159) | Age | ||||
| Pearson correlation | 0.074 | 0.282 | −0.006 | −0.013 | |
| Sig (2-tailed) | 0.360 | <0.001 | 0.943 | 0.870 | |
| BMI | |||||
| Pearson correlation | 0.005 | 0.023 | −0.069 | −0.069 | |
| Sig (2-tailed) | 0.952 | 0.786 | 0.416 | 0.415 | |
| n of psychotropic medications | |||||
| Pearson correlation | −0.055 | 0.021 | −0.030 | −0.031 | |
| Sig (2-tailed) | 0.494 | 0.795 | 0.715 | 0.700 | |
| Quetiapine (n = 73) | Age | ||||
| Pearson correlation | 0.099 | 0.169 | −0.074 | −0.081 | |
| Sig (2-tailed) | 0.414 | 0.161 | 0.549 | 0.511 | |
| BMI | |||||
| Pearson correlation | 0.086 | 0.050 | −0.128 | −0.133 | |
| Sig (2-tailed) | 0.487 | 0.688 | 0.307 | 0.287 | |
| n of psychotropic medications | |||||
| Pearson correlation | 0.030 | −0.096 | −0.084 | −0.083 | |
| Sig (2-tailed) | 0.801 | 0.421 | 0.485 | 0.492 | |
| SSRIs(n = 226) | Age | ||||
| Pearson correlation | 0.064 | 0.247 | −0.40 | 0.60 | |
| Sig (2-tailed) | 0.344 | <0.001 | 0.562 | 0.374 | |
| BMI | |||||
| Pearson correlation | 0.033 | 0.091 | −0.097 | −0.104 | |
| Sig (2-tailed) | 0.638 | 0.185 | 0.160 | 0.133 | |
| n of psychotropic medications | |||||
| Pearson correlation | −0.178 | 0.036 | −0.036 | −0.030 | |
| Sig (2-tailed) | 0.007 | 0.591 | 0.594 | 0.654 | |
| Citalopram (n = 118) | Age | ||||
| Pearson correlation | 0.122 | 0.330 | 0.043 | −0.018 | |
| Sig (2-tailed) | 0.91 | <0.001 | 0.646 | 0.849 | |
| BMI | |||||
| Pearson correlation | 0.105 | 0.148 | 0.009 | −0.045 | |
| Sig (2-tailed) | 0.286 | 0.122 | 0.929 | 0.643 | |
| n of psychotropic medications | |||||
| Pearson correlation | −0.109 | 0.069 | −0.002 | 0.012 | |
| Sig (2-tailed) | 0.240 | 0.457 | 0.984 | 0.895 | |
| Mood stabilizers (n = 69) | Age | ||||
| Pearson correlation | 0.165 | 0.086 | −0.074 | −0.141 | |
| Sig (2-tailed) | 0.186 | 0.491 | 0.553 | 0.259 | |
| BMI | |||||
| Pearson correlation | −0.138 | −0.121 | −0.126 | −0.056 | |
| Sig (2-tailed) | 0.285 | 0.350 | 0.328 | 0.666 | |
| n of psychotropic medications | |||||
| Pearson correlation | −0.096 | −0.026 | 0.153 | 0.148 | |
| Sig (2-tailed) | 0.433 | 0.831 | 0.208 | 0.225 | |
| Polytherapy (n = 184) | Age | ||||
| Pearson correlation | 0.034 | 0.236 | −0.007 | −0.14 | |
| Sig (2-tailed) | 0.649 | 0.002 | 0.929 | 0.851 | |
| BMI | |||||
| Pearson correlation | −0.018 | 0.050 | −0.071 | −0.070 | |
| Sig (2-tailed) | 0.819 | 0.517 | 0.367 | 0.370 | |
| n of psychotropic medications | |||||
| Pearson correlation | −0.072 | 0.038 | −0.064 | −0.060 | |
| Sig (2-tailed) | 0.334 | 0.610 | 0.389 | 0.419 | |
| Total sample (n = 307) | Age | ||||
| Pearson correlation | 0.038 | 0.252 | −0.025 | −0.035 | |
| Sig (2-tailed) | 0.517 | <0.001 | 0.666 | 0.552 | |
| BMI | |||||
| Pearson correlation | −0.11 | 0.053 | −0.090 | −0.093 | |
| Sig (2-tailed) | 0.849 | 0.374 | 0.131 | 0.120 | |
| n of psychotropic medications | |||||
| Pearson correlation | −0.174 | 0.013 | −0.020 | −0.014 | |
| Sig (2-tailed) | 0.002 | 0.823 | 0.732 | 0.805 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Bulatova, N.; Altaher, N.; BaniMustafa, R.; Al-Saleh, A.; Yasin, H.; Zawiah, M.; Khalefah, H.; Ghilan, M.; Al-Lahham, A.; Hudaib, M.; et al. The Effect of Antipsychotics and Their Combinations with Other Psychotropic Drugs on Electrocardiogram Intervals Other Than QTc among Jordanian Adult Outpatients. Biomedicines 2023, 11, 13. https://doi.org/10.3390/biomedicines11010013
AMA Style
Bulatova N, Altaher N, BaniMustafa R, Al-Saleh A, Yasin H, Zawiah M, Khalefah H, Ghilan M, Al-Lahham A, Hudaib M, et al. The Effect of Antipsychotics and Their Combinations with Other Psychotropic Drugs on Electrocardiogram Intervals Other Than QTc among Jordanian Adult Outpatients. Biomedicines. 2023; 11(1):13. https://doi.org/10.3390/biomedicines11010013
Chicago/Turabian StyleBulatova, Nailya, Noor Altaher, Radwan BaniMustafa, Akram Al-Saleh, Haya Yasin, Mohammed Zawiah, Hala Khalefah, Mokhtar Ghilan, Ala’a Al-Lahham, Mohummad Hudaib, and et al. 2023. "The Effect of Antipsychotics and Their Combinations with Other Psychotropic Drugs on Electrocardiogram Intervals Other Than QTc among Jordanian Adult Outpatients" Biomedicines 11, no. 1: 13. https://doi.org/10.3390/biomedicines11010013
APA StyleBulatova, N., Altaher, N., BaniMustafa, R., Al-Saleh, A., Yasin, H., Zawiah, M., Khalefah, H., Ghilan, M., Al-Lahham, A., Hudaib, M., AlKhawaldeh, B., & Nasr, M. (2023). The Effect of Antipsychotics and Their Combinations with Other Psychotropic Drugs on Electrocardiogram Intervals Other Than QTc among Jordanian Adult Outpatients. Biomedicines, 11(1), 13. https://doi.org/10.3390/biomedicines11010013
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
